Patent · US Active

Antibodies that bind CD39 and uses thereof

US10793637B2 · kind B2 · utility

2Cited by

58References

20Claims

0Family size

Assignee

SURFACE ONCOLOGY, LLC · US

Inventors

Scott C. Chappel · Milton, US
Andrew Lake · Cambridge, US
Michael Warren · North Chelmsford, US
Austin DULAK · Reading, US
Erik DEVEREAUX · Hanover, US
Pamela M. Holland · Seattle, US
Tauqeer ZAIDI · Sharon, US
Matthew RAUSCH · Cambridge, US
Bianka Prinz · Lebanon, US
Nels P. Nielson · Cambridge, US
Sonia DAS · Cambridge, US

Key dates

Filing date	May 13, 2020
Grant date	Oct 6, 2020
Priority date	—
Expiry date	May 13, 2040

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/916
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.